Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$2.78B |
| 2 |
Microsoft
MSFT
|
+$2.22B |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$1.67B |
| 4 |
Invesco QQQ Trust
QQQ
|
+$1.65B |
| 5 |
State Street Materials Select Sector SPDR ETF
XLB
|
+$1.19B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.45B |
| 2 |
iShares US Real Estate ETF
IYR
|
+$533M |
| 3 |
State Street Technology Select Sector SPDR ETF
XLK
|
+$410M |
| 4 |
Stellantis
STLA
|
+$312M |
| 5 |
State Street SPDR S&P Biotech ETF
XBI
|
+$240M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.28% |
| 2 | Healthcare | 11.27% |
| 3 | Financials | 10.52% |
| 4 | Consumer Discretionary | 10.12% |
| 5 | Communication Services | 7.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1426
Houlihan Lokey
HLI
$9.03B
| $4.19M | ﹤0.01% |
42,606
+16,886
| +66% | +$1.53M |
|
|
CERE
1427
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $4.18M | ﹤0.01% |
131,342
-469,712
| -78% | -$14.4M |
|
1428
RLI Corp
RLI
$5.94B
| $4.17M | ﹤0.01% |
61,150
-8,048
| -12% | -$535K |
|
|
ITOS
1429
DELISTED
iTeos Therapeutics
ITOS
| $4.17M | ﹤0.01% |
314,880
+57,924
| +23% | +$826K |
|
1430
Pacific Biosciences
PACB
$370M
| $4.14M | ﹤0.01% |
311,356
+156,177
| +101% | +$1.9M |
|
1431
Dycom Industries
DY
$12.2B
| $4.13M | ﹤0.01% |
36,365
+19,092
| +111% | +$1.89M |
|
1432
TechnipFMC
FTI
$27.2B
| $4.12M | ﹤0.01% |
248,152
+5,320
| +2% | +$75K |
|
1433
PVH
PVH
$4.02B
| $4.12M | ﹤0.01% |
48,502
+21,901
| +82% | +$1.85M |
|
1434
Flowserve
FLS
$10.1B
| $4.11M | ﹤0.01% |
110,625
+71,475
| +183% | +$2.48M |
|
1435
Woodward
WWD
$21.5B
| $4.09M | ﹤0.01% |
34,416
-12,033
| -26% | -$1.28M |
|
1436
Community Bank
CBU
$3.42B
| $4.08M | ﹤0.01% |
86,933
+39,538
| +83% | +$1.94M |
|
1437
Gentex
GNTX
$5.09B
| $4.05M | ﹤0.01% |
138,566
+89,836
| +184% | +$2.48M |
|
1438
Ameris Bancorp
ABCB
$5.9B
| $4.05M | ﹤0.01% |
118,450
+46,041
| +64% | +$1.53M |
|
1439
Atlantic Union Bankshares
AUB
$5.94B
| $4.05M | ﹤0.01% |
156,054
+93,876
| +151% | +$2.65M |
|
1440
Avnet
AVT
$7.85B
| $4.05M | ﹤0.01% |
80,187
+24,147
| +43% | +$1.06M |
|
1441
Capri Holdings
CPRI
$1.73B
| $4.03M | ﹤0.01% |
112,179
-31,619
| -22% | -$1.25M |
|
1442
Novavax
NVAX
$1.32B
| $4.02M | ﹤0.01% |
541,555
+73,607
| +16% | +$579K |
|
1443
GoPro
GPRO
$123M
| $4.02M | ﹤0.01% |
971,131
+45,266
| +5% | +$194K |
|
1444
PUT
Warner Bros
WBD
$66.8B
| $4.01M | ﹤0.01% |
320,000
| – | – |
|
1445
iShares Core MSCI Emerging Markets ETF
IEMG
$155B
| $4.01M | ﹤0.01% |
81,323
-439,469
| -84% | -$21.5M |
|
1446
CALL
Starbucks
SBUX
$121B
| $4M | ﹤0.01% |
+40,400
| New | +$4.19M |
|
1447
HealthEquity
HQY
$8.8B
| $3.99M | ﹤0.01% |
63,181
+9,670
| +18% | +$561K |
|
1448
First Bancorp
FBP
$4.4B
| $3.99M | ﹤0.01% |
326,447
+115,232
| +55% | +$1.34M |
|
1449
Visteon
VC
$2.79B
| $3.98M | ﹤0.01% |
27,730
+4,547
| +20% | +$648K |
|
1450
Atkore
ATKR
$3.16B
| $3.97M | ﹤0.01% |
25,489
-105,102
| -80% | -$13.8M |
|
Similar funds
Barclays's Q2 2023 Portfolio in Review
As of Q2 2023, Barclays held 5,371 positions worth $158B, down 28% from $218B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Barclays withdrew a net $70.1B in Q2 2023, closing 872 positions and reducing 1,669 holdings. Its most notable exit was DCP Midstream, LP, an estimated $47.3M position sold in full.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 12% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Barclays opened a new position in State Street SPDR Nuveen ICE Municipal Bond ETF worth $36.9M.
- Barclays's largest Q2 2023 buy was State Street SPDR Nuveen ICE Municipal Bond ETF: 799,988 shares worth $36.9M.
- Barclays added most to Apple in Q2 2023, an estimated $2.78B increase.
- Barclays's biggest Q2 2023 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.45B.
- Barclays fully exited DCP Midstream, LP in Q2 2023, selling an estimated $47.3M.
- Barclays's ten largest holdings make up 24% of its $158B portfolio in Q2 2023.
- Barclays opened 314 new positions and closed 872 in Q2 2023.
- Barclays's portfolio value fell 28% quarter-over-quarter to $158B.
Based on Barclays's 13F filing for Q2 2023, filed 3 Aug 2023.